orserdu
stemline therapeutics b.v. - elacestrant - bröst-neoplasmer - endokrin terapi - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.
aldactone 100 mg filmdragerad tablett
pfizer ab - spironolakton - filmdragerad tablett - 100 mg - spironolakton 100 mg aktiv substans - spironolakton
spironolakton orifarm 100 mg tablett
orifarm healthcare a/s - spironolakton - tablett - 100 mg - spironolakton 100 mg aktiv substans; natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne - spironolakton
spironolakton pfizer 100 mg tablett
pfizer ab - spironolakton - tablett - 100 mg - spironolakton 100 mg aktiv substans; laktosmonohydrat hjälpämne - spironolakton
aldactone 25 mg filmdragerad tablett
pfizer ab - spironolakton - filmdragerad tablett - 25 mg - spironolakton 25 mg aktiv substans - spironolakton
spironolakton orifarm 25 mg tablett
orifarm healthcare a/s - spironolakton - tablett - 25 mg - spironolakton 25 mg aktiv substans; natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne - spironolakton
spironolakton pfizer 25 mg tablett
pfizer ab - spironolakton - tablett - 25 mg - laktosmonohydrat hjälpämne; spironolakton 25 mg aktiv substans - spironolakton
aldactone 50 mg filmdragerad tablett
pfizer ab - spironolakton - filmdragerad tablett - 50 mg - spironolakton 50 mg aktiv substans - spironolakton
spironolakton pfizer 50 mg tablett
pfizer ab - spironolakton - tablett - 50 mg - spironolakton 50 mg aktiv substans; laktosmonohydrat hjälpämne - spironolakton
spironolakton orifarm 50 mg tablett
orifarm healthcare a/s - spironolakton - tablett - 50 mg - laktosmonohydrat hjälpämne; spironolakton 50 mg aktiv substans; natriumlaurilsulfat hjälpämne - spironolakton